Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Infographic: RA Perceptions

    August 25, 2015 | Biologics, physicians, rheumatoid arthritis 

    HCPs predict the future of the biologics market

    Findings from a recent survey of physicians across Europe has revealed that, despite stiff competition from newer biologics, biosimilars and pipeline agents, physicians expect current market leaders Enbrel (etanercept) and Humira (adalimumab) to continue to lead the market and be used to treat over a third of Rheumatoid Arthritis (RA) patients in three years’ time. Nevertheless, the anti-TNF segment is predicted to experience a strong downturn with a 19% loss in share in the same period.

    Download our RA Perceptions: Predicting the future of the European market infographic now »

    RA Perceptions is a market research study which is carried out every month amongst a panel of 200 physicians across five European countries (France, Germany, Italy, Spain and the UK) and asks physicians about current and future perceptions of the RA market. These findings are from the June survey. RA Perceptions is a component of a larger ongoing patient tracking study called Therapy Watch RA, conducted by global healthcare market research specialist Research Partnership. An infographic highlights the key findings from the study.

    Biologic agents with novel mechanisms of action (such as Roche’s RoActemra) are expected to outperform the overall EU biologics market with 15% growth over the next 3 years.

    Biosimilars (the approved follow-on products to innovator biologics) will benefit from the greatest gains. Physicians predict a four-fold increase in their use of Hospira’s Inflectra and Celltrion’s Remsima. Despite heavy discounting of some biosimilars in certain markets such as France, the overall market share for these infliximab biosimilars is projected to remain relatively small. Less than 25% of physicians currently report prescribing biosimilars.

    Overall, physicians’ awareness of pipeline agents in RA is low. The greatest levels of familiarity and interest were reported for novel small molecules such as Celgene’s Otezla (apremilast) and Pfizer’s Xeljanz (tofacitinib), which both offer a new oral alternative for patients who fail to respond adequately or are intolerant to traditional disease modifying treatments. Of the physicians who were familiar with these agents, 89% said they would prescribe Otezla and 83% stated they would prescribe Xeljanz, in the next 3 years.

    The RA biologics market is expected to undergo significant changes in the next few years as newer entrants compete with established brands and biosimilars become increasingly accepted for use as cheaper alternatives to the branded biologics.

    This content was provided by Inizio

    Company Details

    - PMLiVE

    Inizio

    Email
    Website

     Latest Content from  Inizio 

    Eliminating Stigma: A consideration of the role the pharmaceutical industry can play

    My recent article in Medical Marketing & Media explored the importance of vaccine perceptions in a self-pay market and touched upon the issue of stigma, with the recognition that some diseases or...

    Fighting talk

    One thing that grasps my interest is how society has adopted military style language when talking about cancer

    Is MINT the next BRIC?

    In 2001, British economist Jim O’Neill coined the now ubiquitous acronym ‘BRIC’, to stand for the four emerging economies of Brazil, Russia, India and China, which he suggested were all...

    The healthcare market research themes for 2014

    As we shake off our winter coats and prepare for what will hopefully be a long, hot summer, the 2014 themes for healthcare and market research are emerging.

    Big Data—a new player in the Healthcare Industry

    Big Data is an exciting by-product of the information technology revolution and offers new ways of understanding customers.

    Blog: Affordable Care Act

    What does the future hold for the US pharma industry?

    Webinar: How to conduct effective market research in emerging markets

    Pharmaceutical market research is still evolving in many emerging markets and so finding the insights you require can be a challenge.

    Webinar: Uncovering hidden insights into patient compliance

    Pharma companies are increasingly looking for ways to provide “beyond the pill" services to support patients with the management of their disease. Adherence tools and programs encourage patients to stay compliant with their treatment...

    Webinar: The patient journey: Time to look beyond the physician?

    Treatment initiation is a key focus for many pharma companies as part of their strategy to increase script writing and drive greater revenues.

    Webinar: Ensuring an actionable segmentation

    One of the most consistent issues researchers face with segmentation is ensuring that it is actionable.